《大行報告》里昂升中生製藥(01177.HK)目標價至10.56元評級「買入」
里昂發表報告指,中生製藥(01177.HK)公布其重磅藥品安羅替尼獲國家藥監局頒發藥品註冊批件,批准新增適應症「軟組織肉瘤」,集團在過去一個月亦獲得另外四種仿制藥的生產許可。此外,集團旗下藥品Alprostadil (Kaishi)亦被列入內地近期公布的全國重點監控目錄。
該行相信,Alprostadil (Kaishi) 對集團的影響甚少,因該藥僅貢獻集團去年收入的3.6%,今年則料佔2.8%。考慮安羅替尼新增適應症對收入的貢獻,里昂上調對中生製藥的股份目標價,由9.18元升至10.56元,評級維持「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.